Skin of Color Considerations in Aesthetics
Cheryl Burgess, MD, will share pearls on counseling patients on appropriate cosmetic procedures for their skin type, safety measures, and strategies to achieve desired outcomes.
What to Expect at the 2023 Inflammatory Disease Summit
The inaugural IDS meeting geared towards physician assistants and nurse practitioners begins the first day of Fall Clinical in Las Vegas.
Exploring the Best of Las Vegas During Fall Clinical
Looking to explore the city between Fall Clinical sessions or to extend your stay? Check out this top 10 list of the best Las Vegas has to offer in October.
What to Expect at the 2023 Fall Clinical Dermatology Conference
One of the largest dermatology meetings of the year kicks off today with an exciting line up of expert perspectives and clinical pearls. Here's what you can expect.
POLL: Are You Attending the 2023 Inflammatory Disease Summit?
Click here to answer if you're attending IDS 2023.
Delving Into Fall Clinical 2023 With Del Rosso
One of the many minds behind innovative Fall Clinical Dermatology sessions gives a sneak peek of the top 5 things to look forward to during this year's meeting.
POLL: Are You Attending the 2023 Fall Clinical Dermatology Conference?
Click here to answer if you're attending Fall Clinical.
Previewing Dermatology Times Editorial Advisory Board Member Sessions: Fall Clinical Dermatology Conference
Among the many sessions to be held at the 2023 Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.
Shawn Kwatra, MD, Reviews Late-Breaking Data of Abrocitinib for Prurigo Nodularis and Chronic Pruritus of Unknown Origin
Kwatra presented the abrocitinib data at EADV 2023.
Incyte Announces Expanded TRuE-AD3 Data at EADV
The expanded study data correlates with the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis.
MoonLake Immunotherapeutics Announces 24-Week Data of Sonelokimab for HS
After maintenance treatment with sonelokimab dosed every 4 weeks, 57% of patients achieved HiSCR75 at week 24.
Treatment-Related Acne After Ruxolitinib Application for Vitiligo Occurred in Patients Without History of Acne
Overall, acne events were mild or moderate and did not cause patients to discontinue ruxolitinib cream treatment.
Trevi Therapeutics Announces New Phase 2b/3 Results of Haduvio for Prurigo Nodularis
The continued reduction in WI-NRS was seen in patients who remained in the study through week 52.
Bimekizumab Achieved Meaningful Clinical Improvements in Hidradenitis Suppurativa, According to Data From EADV
UCB presented data from the BE HEARD I and BE HEARD II phase 3 studies at this year's EADV Congress.
Amlitelimab Significantly Improves Average EASI Scores in Phase 2b AD Study
Sanofi’s phase 3 program for amlitelimab in atopic dermatitis will start in early 2024.
ADvantage, ADvocate Studies Support Clinical Improvements of AD With Lebrikizumab
Almirall presented new data on lebrikizumab at EADV related to clinical improvements and clinically-meaningful treatment responses among patients with atopic dermatitis.
Arcutis Presents Positive Roflumilast Foam Data From ARRECTOR Trial in Scalp and Body PsO at EADV
At week 8, 65.3% of roflumilast-treated patients achieved a clinically significant reduction in itch.
Upadacitinib Meets Primary End Point of Phase 2 Trial for Vitiligo and Advances to Phase 3
AbbVie announced the 24- and 52-week data at EADV 2023.
Interim Data From Almirall's POSITIVE Study Reveals Significant Well-Being Improvements Among Psoriasis Patients
Patients and their families experienced significant improvements to well-being with tildrakizumab use in as little as 16 weeks.
Eric Simpson, MD, Discusses Recently Announced EADV Data On Tapinarof Cream for AD Down to 2 Years
New data from ADORING 1 and ADORING 2 show a rapid reduction in pruritus relief as early as 24 hours after the first application.